Therapeutic Advances in Vaccines and Immunotherapy

Different drug approaches to COVID-19 treatment worldwide: an update of new drugs and drugs repositioning to fight against the novel coronavirus

Josidel Conceição Oliver*, Evandro Neves Silva*, Leticia Martins Soares*, Gislaine Cristina Scodeler, Ana de Souza Santos, Patricia Paiva Corsetti, Carlos Roberto Prudência and Leonardo Augusto de Almeida

Abstract: According to the World Health Organization (WHO), in the second half of 2022, there are about 606 million confirmed cases of COVID-19 and almost 6,500,000 deaths around the world. A pandemic was declared by the WHO in March 2020 when the new coronavirus spread around the world. The short time between the first cases in Wuhan and the declaration of a pandemic initiated the search for ways to stop the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or to attempt to cure the disease COVID-19. More than ever, research groups are developing vaccines, drugs, and immunobiological compounds, and they are even trying to repurpose drugs in an increasing number of clinical trials. There are great expectations regarding the vaccine’s effectiveness for the prevention of COVID-19. However, producing sufficient doses of vaccines for the entire population and SARS-CoV-2 variants are challenges for pharmaceutical industries. On the contrary, efforts have been made to create different vaccines with different approaches so that they can be used by the entire population. Here, we summarize about 8162 clinical trials, showing a greater number of drug clinical trials in Europe and the United States and less clinical trials in low-income countries. Promising results about the use of new drugs and drug repositioning, monoclonal antibodies, convalescent plasma, and mesenchymal stem cells to control viral infection/replication or the hyper-inflammatory response to the new coronavirus bring hope to treat the disease.

Keywords: clinical trials, COVID-19, drug repositioning, new coronavirus, SARS-CoV-2

Received: 13 September 2022; revised manuscript accepted: 18 November 2022.
SARS-CoV-2 led the WHO to announce the pandemic status, with many countries presenting increasing number of COVID-19 cases from March 2020 to June 2021, mainly in Europe, where a so-called second wave of infection is decreasing now. In the United States, an uncontrolled increase in infection was observed with rapid decrease after vaccination, different from India and Brazil, comprising almost 50% of confirmed cases around the world. Due to the severe characteristics of the disease, the augmentation of intensive care of hospitalized patients, and the lack of specific drugs, the entire world has been searching for effective therapies for the treatment of COVID-19. According to ClinicalTrials.gov, about 8160 clinical trials involving the diagnosis, prevention, or treatment of COVID-19 were in progress until August 2022, and that number is increasing every day. Here, we intend to describe the clinical trials undertaken around the world for the treatment of COVID-19 and to point out the differences in the approaches used. Most of these clinical trials are being conducted in the countries of Europe and the United States, performing more than 50% of those when compared with total trials (Figure 1). As for the type of clinical trial, most involve drug evaluation, biologics (such as vaccines and convalescent plasma), and, in smaller numbers, cell therapies, mechanical ventilation, diagnostic tests, and telemedicine (Figure 2).

Methods
The present review was developed through the search for information on clinical trials involving the diagnosis, prevention, or treatment of COVID-19 worldwide. ClinicalTrials.gov was the clinical trials database used for this search. It took place in October 2020 and was updated in August 2022, because the number of clinical trials is increasing or updating every day. Articles on COVID-19, indexed in the databases Web of Science, PubMed, and Scholar Google, with perspectives on diagnosis, prevention, or treatment, were also included in the study. Articles that did not bring any new information were excluded after a full reading. The review is based on drugs (new drugs and drugs repositioning), monoclonal antibodies, convalescent plasma, and mesenchymal cell therapy to control the deleterious effect of COVID-19.

Figure 1. Clinical trials involving the diagnosis, prevention, or treatment of COVID-19 worldwide are concentrated in the United States and Europe. Circles represent the number of clinical trials in that region of the world proportionally. Red represents the clinical trials present in the region indicated in the map compared with the total clinical trials in other areas (gray).
Drugs
In addition to developing new treatment options, such as new drugs, immunotherapies, and host-directed therapies, scientists worldwide continue to simultaneously explore the efficacy of existing drugs against SARS-CoV-2. From ClinicalTrials.gov, we found 4148 clinical trials that evaluated drugs in the treatment of COVID-19 until the month of August 2022. These drugs can be divided into two broad categories: those that can directly target the virus replication cycle and those based on immunotherapy approaches aimed at boosting innate antiviral immune responses or alleviating damage induced by dysregulated inflammatory responses.

New drugs for COVID-19
We considered new drugs for COVID-19 to be drugs that were not previously associated with studies of other diseases (Table 1). Some of the drugs with promising results are PF-07304814, DFV890, RBT-9, TD-0903, M5049, BLD-2660, and SNG001 (Figure 3).

PF-07304814: The designed phosphate prodrug PF-07304814 is metabolized to PF-00835231, which is a potent inhibitor in vitro of the SARS-CoV-2 3CL protease in preclinical studies.7,8 PF-00835231 exhibits potent in vitro antiviral activity against SARS-CoV-2 as a single agent. It is additive/synergistic in combination with remdesivir and can be more potent than remdesivir.7,8 This drug was developed by Pfizer, and it is being evaluated in phase I clinical trials (clinical trial number NCT04535167) in hospitals in the United States.

DFV890: Developed by Novartis, and the efficacy and safety of DFV890 for the treatment of COVID-19 patients with pneumonia and impaired respiratory function, it is being assessed in phase II clinical trials (NCT04382053). The clinical trials involve patients from 12 different countries: Argentina, Brazil, Denmark, Germany, Hungary, India, Mexico, the Netherlands, Peru, the Russian Federation, South Africa, and Spain (recruitment status completed).

RBT-9: This drug is being developed by Renibus Therapeutics as an antiviral with organ-protective characteristics. Renibus Therapeutics will conduct phase II trials of this compound with antiviral and immune-modulating activity to evaluate...
Table 1. New drugs developed to treatment COVID-19.

| Drug          | Drug category       | Study title                                                                                       | Sponsors                | Current phase | NCT number  | Locations                                                                 |
|---------------|---------------------|--------------------------------------------------------------------------------------------------|-------------------------|---------------|-------------|---------------------------------------------------------------------------|
| DFV890        | Antiviral           | Study of Efficacy and Safety of DFV890 in Patients With COVID-19 Pneumonia                      | Novartis               | Phase II      | NCT04382053 | Argentina, Brazil, Denmark, Germany, Hungary, India, Mexico, the Netherlands, Peru, Russian Federation, South Africa, and Spain |
| PF-07304814   | Antiviral           | First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending Dose And Extended Infusion of PF 07304814 In Hospitalized Participants With COVID-19 | Pfizer                 | Phase I       | NCT04535167 | United States of America                                                 |
|               |                     | Study to Investigate the Mass Balance, Metabolism, and Excretion of [14 C]-PF-07304814 in Healthy Participants | Pfizer                 | Phase I       | NCT05050682 | United States of America                                                 |
|               |                     | ACTIV-3: Therapeutics for Inpatients With COVID-19                                               | University of Minnesota | Phase III     | NCT04501978 | ACTIV-3: Therapeutics for Inpatients With COVID-19                         |
| RBT-9         | Antiviral and immunomodulator | A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals [The PREVENT Study] | Renibus Therapeutics, Inc. | Phase II     | NCT04364763 | United States of America                                                 |
|               |                     | Efficacy of Sunlight Activated Synthetic Porphyrin in COVID-19 Infected Patients                 | Kafrelsheikh University | Phase I       | NCT04371822 | Egypt                                                                     |
| SAR443122     | Immunomodulator [RIPK1 Inhibitor] | A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19 | Sanofi                  | Phase I       | NCT04469621 | Argentina, Brazil, Chile, Mexico and Russian Federation                   |
| TD-0903       | Immunomodulator [JAK inhibition] developed for the treatment of acute lung injury due to COVID-19 | TD-0903 for ALI Associated With COVID-19                                                          | Theravance Biopharma   | Phase II      | NCT04402866 | Republic of Moldova, Romania, Ukraine, and United Kingdom                 |
|               |                     | TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation             |                         | Phase I       | NCT05091723 | United States, California                                                 |
| Drug | Drug category | Study title | Sponsors | Current phase | NCT number | Locations |
|------|---------------|-------------|----------|---------------|------------|-----------|
| RLS-0071 | Immunomodulator. Novel peptide developed for the treatment of acute lung injury due to COVID-19 | A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure | ReAlta Life Sciences, Inc. | Phase I | NCT04574869 | United States of America |
| | | A Phase 1 SAD/MAD Study of RLS-0071 in Healthy Volunteers in Support of a COVID-19 Development Program | ReAlta Life Sciences, Inc. | Phase I | NCT05298787 | Canada, Quebec |
| M5049 | Immunomodulator. A novel potent and selective inhibitor of toll-like receptors 7 and 8 | M5049 Study in Participants With Coronavirus Disease 2019 (COVID-19) Pneumonia | EMD Serono Research & Development Institute, Inc. | Phase II | NCT04448756 | Brazil and United States of America |
| EG-HPCP-03a | Unknown* | Study to Evaluate the Efficacy and Safety of EG-HPCP-03a Compared to DEX in Patients With COVID-19 Pneumonia. | Evergreen Therapeutics, Inc. | Phase II | NCT04561180 | Unknown* |
| COVID19-0001-USR | Unknown* | Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient | United Medical Specialties | Phase I/II | NCT04595136 | Colombia |
| PHR160 Spray | Unknown* | Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19 | Baqiyatallah Medical Sciences University | Not applicable | NCT04463420 | Iran, Islamic Republic of |
| BLD-2660 | Unknown* | Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects | Blade Therapeutics and Clinpace Worldwide | Phase II | NCT04334460 | California, District of Columbia, Florida, Idaho, Illinois, Iowa, Kentucky, Maryland, Michigan, Nebraska, New Jersey, North Carolina, Pennsylvania, South Carolina, Tennessee, Texas, Washington, Brazil |
| | | Safety, Pharmacodynamics, and Pharmacokinetics of Orally Administered BLD-2660 in Subjects With IPF | Blade Therapeutics | Phase II | NCT04244825 | United Kingdom |

(Continued)
| Drug                  | Drug category | Study title                                                                 | Sponsors                          | Current phase | NCT number   | Locations                                      |
|----------------------|---------------|------------------------------------------------------------------------------|-----------------------------------|---------------|--------------|------------------------------------------------|
| Healthy Volunteer Study Comparing Tablet and Capsule Formulations |               | Blade Therapeutics                                                           | Phase I             | NCT04001998 | Australia, New South Wales                      |
| First in Human Study in Healthy Volunteers Followed With Dosing in Participants With Lung or Liver Fibrosis |               | Blade Therapeutics                                                           | Phase I             | NCT03559166 | Australia, Victoria                             |
| SNG001II             | Antiviral     | Trial of Inhaled Anti-viral [SNG001] for SARS-CoV-2 [COVID-19] Infection     | Synairgen Research Ltd.           | Phase II      | NCT04385095 | United Kingdom                                  |
|                      |               | Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19 | Synairgen Research Ltd.           | Phase III     | NCT04732949 | United States, Arizona and 111 locations        |
|                      |               | Comparing Efficacy and Safety of Inhaled SNG001 to Placebo                   | Synairgen Research Ltd.           | Phase II      | NCT01126177 | United Kingdom                                  |
|                      |               | A Study to Test a Potential New Treatment for COPD Patients Suffering From the Common Cold or Influenza | Synairgen Research Ltd.           | Phase II      | NCT03570359 | United Kingdom                                  |
|                      |               | Pilot Test of COVID-19 Related Clinical Outcome Assessment Methodology and Qualitative Evidence of Content Validity | Synairgen Research Ltd.           | Phase I       | NCT05207293 | United States, Michigan                         |
|                      |               | ACTIV-2: A Study for Outpatients With COVID-19                               | National Institute of Allergy and Infectious Diseases [NIAID] | Phase II/III  | NCT04518410 | United States, Alabama and 250 locations        |
| LAU-7b               | Unknown*      | Study of LAU-7b for the Treatment of COVID-19 Disease in Adults [RESOLUTION] | Laurent Pharmaceuticals Inc.     | Phase II      | NCT04417257 | Idaho, Maryland, Michigan, British Columbia, Quebec |
| Paxlovid             | Antiviral     | Efficacy and Safety Evaluation of Paxlovid for COVID-19: a Real-world Case-control Study | Ruijin Hospital                  | Not applicable| NCT05532852 | China, Shanghai                                 |
|                      |               | A Real World Study of Paxlovid for the Treatment of Hospitalized Patients Confirmed With COVID-19 | Huashan Hospital                 | Phase I       | NCT05387369 | China                                          |
| Drug                                                        | Drug category                                                                 | Study title                                                                 | Sponsors                        | Current phase | NCT number      | Locations                      |
|--------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------|---------------------------------|---------------|-----------------|--------------------------------|
| Paxlovid in the Treatment of COVID-19 Patients With Uremia   |                                                                                |                                                                              | Ruijin Hospital                 | Phase I       | NCT05386433     | Unknown*                      |
| Efficacy and Safety of JT001 [VV116] Compared With Paxlovid  |                                                                                |                                                                              | Vigonvita Life Sciences         | Phase III     | NCT05341609     | China, Shanghai               |
| General Investigation for PAXLOVID PACK                       |                                                                                |                                                                              | Pfizer                          | Unknown*      | NCT05263908     | Japan                         |
| A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease |                                                                                |                                                                              | Pfizer                          | Phase I       | NCT05487040     | Unknown*                      |
| A Study to Learn About the Study Medicine [Called Nirmatrelvir/Ritonavir] in Pregnant Women With Mild or Moderate COVID-19 |                                                                                |                                                                              | Pfizer                          | Phase I       | NCT05386472     | United States, California     |
| The Safety of Paxlovid in Hemodialysis Patients With Covid-19 |                                                                                |                                                                              | Ruijin Hospital                 | Phase IV      | NCT05366192     | China, Shanghai              |
| Randomised Evaluation of COVID-19 Therapy                     |                                                                                |                                                                              | University of Oxford           | Phase II/III  | NCT04381936     | Ghana, India, Indonesia, Nepal, United Kingdom |
| Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19 |                                                                                |                                                                              | Deutsches Rotes Blutspendedienst Baden-Wurttemberg | Phase III     | NCT05271929     | France, Germany, United Kingdom |

Structures, when available, were obtained from PubChem, an open chemistry database at the National Institutes of Health [NIH].

*No information was found regarding this one.*
the efficacy, tolerability, and safety of a single dose of RBT-9 versus placebo in COVID-19 infection in non-critically ill adults who are at high risk of progression (NCT04364763).

TD-0903: It is a lung-selective, nebulized pan-JAK inhibitor that was discovered and developed by Theravance Biopharma for the treatment of acute lung injury associated with COVID-19. Through its mechanism, TD-0903 has the potential to broadly inhibit Janus kinase/signal transducers and activators of transcription (JAK-STAT) signaling in airways, blocking the release of cytokines and chemokines that may be associated with acute lung injury and the initiation of a cytokine storm syndrome. Preclinical studies suggest that TD-0903 has a very high lung-to-plasma ratio and rapid metabolic clearance, resulting in low systemic exposure, which is compatible with its lung selectivity. TD-0903 is administered via a nebulised inhalation solution, which further enhances its lung selectivity. Preclinical pharmacodynamic studies indicate that TD-0903 has an extended duration of action that should enable once or twice daily dosing in humans [two studies, both with recruitment status completed: one in phase I (NCT04350736) and the other in phase II (NCT04402866)].

M5049: First-in-class small molecule blocks the activation of Toll-like receptor (TLR) 7 and TLR8, which are two innate immune sensors that detect single-stranded RNA from viruses such as the SARS-CoV-2 genome. The activation of TLR7/8 leads to immune cell activation and inflammation, which, when not properly controlled, can cause severe immunopathology. Merck will initiate a phase II randomized controlled clinical study evaluating the safety and efficacy of M5049, aiming to prevent or ameliorate the hyper-inflammatory response and to prevent progression to cytokine storm syndrome in COVID-19 patients.

BLD-2660: Novel, synthetic, orally active small molecule inhibitor of calpain 1, 2, and 9...
is selective over the cathepsins as well as other protease families. It displays good metabolic stability and permeability, oral bioavailability, and low cytochrome P450 inhibition. It is under development for the treatment of patients with COVID-19 in phase II clinical trials in the US and Brazil hospitals (NCT04334460).

SNG001: This is an inhaled drug that contains an antiviral protein called interferon beta (IFN-β). Many viruses inhibit IFN-β as part of their strategy to evade the immune system. IFN-β protects cells against the MERS and SARS coronaviruses. SNG001 is in phase II clinical trials for COVID-19 (NCT04385095) and chronic obstructive pulmonary disease (COPD) (NCT03570359) and two more studies, NCT04732949 in phase III and NCT04518410 in phase II/III.

Drugs repositioning for COVID-19 treatment

Pandemics, such as the COVID-19 pandemic, create unique challenges for health professionals, such as the selection of appropriate treatments and the lack of time available for drug discovery. Most of the clinical trials evaluate drug repositioning to control viral infection using antivirals or other drugs of similar effect, such as antiparasitic and antibacterial drugs. In addition, there are several clinical trials that are evaluating anti-inflammatory drugs, antineoplastics, antioxidants, food supplements, and medications related to cardiovascular diseases, glycemia, and lipid diseases (Table 2).

Antiviral drugs to treat COVID-19. We found 653 drugs developed for viral infections, such as hepatitis, HIV, Ebola, influenza, yellow fever, Zika, and Chikungunya, which are being tested to treat patients with COVID-19 (Table 2). Some drugs can inhibit viral replication (e.g. favipiravir, remdesivir, and ribavirin) or inhibit viral entry (e.g. lopinavir–ritonavir and umifenovir).9

Molnupiravir is a small-molecule antiviral prodrug that is converted in plasma to NHC [N(4)-Hydroxycytidine] and then to the 5’-triphosphate form by host cell kinases.10 In phase II clinical trials (NCT04405570 and NCT04405739), the drug showed efficacy against infections of the Wuhan strains (B.1.1.7 and B.1.351), with the potential to combat the worrisome variants of SARS-CoV-2.11 In phase II studies (NCT04939428), with 202 unvaccinated participants, with confirmed SARS-CoV-2 infection, receiving 200–800mg of molnupiravir or placebo, orally twice a day for 5 days, showed accelerated clearance of SARS-CoV-2 RNA and clearance of the infectious virus.10 In phase III studies (NCT04575597), the drug has been shown to provide early treatment decreasing the risk of hospitalization or death in at-risk and unvaccinated adults.12 Until now, the results in clinical trials suggest that molnupiravir works to reduce the chances of the SARS-CoV-2 virus multiplying in the body, making it possible to treat COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of disease progression.

Remdesivir was developed for the treatment of RNA-based viruses and showed efficient against Ebola virus and Coronaviridae family viruses exemplified by MERS and SARS.13–15 This drug can be incorporated into nascent viral RNA and further inhibit the RNA-dependent RNA polymerase, inducing premature termination of viral RNA transcription.13 Recent in vitro studies have shown that remdesivir is a potent SARS-CoV-2 inhibitor, which can justify the ongoing clinical trials for the treatment of COVID-19.6,16,17 Grein et al.18 observed clinical improvement in 68% of patients hospitalized for severe COVID-19 who were treated with remdesivir. Another study showed clinical improvement using remdesivir, with a median recovery time of 10 days, as compared with 15 days among those who received placebo. Furthermore, the mortality was lower for the remdesivir-treated patients when compared with those who received placebo.19

Favipiravir effectively inhibits the RNA-dependent RNA polymerase and viral replication.17 The effectiveness in vitro against influenza viruses, Ebola virus, and SARS-CoV-2 was described.15,16 In 67 clinical trials, favipiravir is being investigated alone or in combination with other drugs to treat COVID-19. Favipiravir was shown to partially control inflammatory mediators in COVID-19 patients. However, the inflammation and cytokine storm continued after favipiravir administration that could be controlled with steroids.20 Cai et al.21 conducted an open-label control study where favipiravir + IFN-α exhibited faster viral clearance and radiological improvement compared with the lopinavir/ritonavir + IFN-α group.
Table 2. Repositioned drugs for treatment of COVID-19 being evaluated within 4148 clinical trials at ClinicalTrial.gov.

| Drug class or therapeutic target                  | Drugs                                                                 |
|--------------------------------------------------|------------------------------------------------------------------------|
| Adrenoleukodystrophy                             | OP-101                                                                 |
| Alcoholic hepatitis                              | DUR-928                                                                |
| Alcoholism                                       | Disulfiram, Naltrexone, Ketamine, Azudine                              |
| Angina                                           | T89 or Dantonic, Atorvastatin                                          |
| Angioedema                                       | Ruconest, ISIS 721744, TXA127                                          |
| Antiarrhythmic                                   | Amiodarone, Verapamil, Losartan, Amiodarone                            |
| Anti-bacterial                                   | Azithromycin, Amoxicillin/Clavulanate, Ceftriaxone, Cetylpyridinium      |
| Anti-cancerogenic/antineoplastic                 | Abivertinib maleate, Acalabrutinib, Apilimod dimesylate, Antroquinonol |
| Anti-emetic                                      | Tradipitant                                                            |
| Anti-hyperglycemic                               | Dapagliflozin, Icosapent ethyl, Linagliptin, Metformin, Pioglitazone    |
| Antihypertensive                                 | Amlodipine, Captopril, Ilenprodel, Losartan, Prazosin, Propranolol      |
| Antimigraine                                     | Zavegepant                                                             |
| Antiparasitic                                    | Artemisinin, Atovaquone, Chloroquine/Hydroxychloroquine, Ivermectin    |
| Antiviral                                        | Atazanavir, Azvudine, Cenicriviroc, Clevudine, Cobicistat, Daclatasvir  |
| Anti-coagulation/anti-thrombotic/antiaggregant    | Alteplase, Apixaban, Aspirin, Be miparin, Clopidogrel, Diosmin, Dipyr idamole |
| Anti-thrombocytopenia                            | Ettrombopag, rhTPO                                                     |
| Antifibrinolytic                                 | Aprotinin                                                              |
| Anemia                                           | Crizanlizumab, Desidustat, Protoporphyrin and Sulfonatoporphyrin       |

(Continued)
**Table 2.** (Continued)

| Drug class or therapeutic target | Drugs |
|----------------------------------|-------|
| Chronic iron overload            | Deferoxamine |
| Cholesterol                      | Atorvastatin, Rosuvastatin, Simvastatin |
| Epigenetic regulator             | NuSepin, DUR-928 |
| Fluid retention                   | Spironolactone |
| Food supplement                   | N-acetyl cysteine, Omega 3, Prolectin-M, Vitamin C, Vitamin D, Vitamin E, Zinc |
| Gastrointestinal disorders        | Inhibitor of gastric acid secretion |
| Pancreatitis                      | TAK-671 |
| Probiotic                         | Probiorinse, Omnibiotic |
| Serine protease inhibitor to neutralize digestive enzymes | LB1148 |
| Gene therapy                      | DeltaRex-G, PD-1 |
| Immunomodulator                   | Avdorallamb, Axatilimab, Azoximer bromide, Bardoxolone, Calciferol, Collagen-Polyvinylpyrrolidione, Camostat mesylate, Cyclosporine, Dapansutile, Emapalumab, Fostamatinib, Meplazumab, Molgramostim, Monalizumab, Nangibotide, NuSepin, Rapamycin, Risankizumab, Secukinumab, Thyamfasin, Tacrolimus, Ulinastatin, APL-9, AMY-101, BDB-001, CERC-002, ViB7734 |
| Corticosteroid                    | Budesonide, Ciclesonide, Dexamethasone, Hydrocortisone, Methylprednisolone, Mometasone furoate, Ophtamesone, Prednisone |
| Anti-inflammatory                 | Astegolimab, Colchicine, Icatibant, Ibudilast, Ibuprofen, Isotretinoin, Losmapimod, ABX464, EDP1867, GLS-1027, SAR443122 |
| Anti-inflammatory and antioxidant | Ebselen, Fisetin, Silymarin |
| Anti-inflammatories used against rheumatoid arthritis | Abatacept, Anakinra, Apremilast, Baricitinib, Bucillamine, Canakinumab, Clazakinumab, Leflunomide, Otilimab, Sarilumab, Sirukumab, Tocilizumab, Tofacitinib, PF-06650833 |
| Non-steroidal anti-inflammatory, inhibitor of cyclooxygenases 1 and 2 | Acetylsalicylic acid, Naproxe, Indomethacin |
| Calcium channel blocker with anti-inflammatory effects | Tetrandrine |
| Metabolic syndrome               | Treamid |

(Continued)
### Table 2. (Continued)

| Drug class or therapeutic target | Drugs |
|----------------------------------|-------|
| **Monoclonal antibodies**        | Acalabrutinib, Astegolimab, Avdoralimab, Axatilimab, Canakinumab, Clazakizumab, Crizanlizumab, Duvelisib, Eculizumab, Emapalumab, Gimsilumab, Garadacimab, Infliximab, Iitolizumab, Lanadelumab, Lenzilumab, Leronlimab, Levilimab, Mavrilimumab, Meplazumab, Monalizumab, Nivolumab, Olokizumab, Otilimab, Pavrevelumab, Ravulizumab, Risankizumab, Sarilumab, Secukinumab, Siltuximab, Sirukumab, Tocilizumab, AK119, BGB-DXP593, BMS-986253, BRII-196, BRIII-198, CERC-002, CPI-006, CT-P59, CSL324, IC14 (Anti-CD14), JS016, LY3127804, MAS825, REGN10933 + REGN10987, SCTA01, STI-1499 [COVI-GUARD], STI-2020 [COVI-AMG™], TJ003234, TY027, VIR-7831 |
| **Natural disorders**            | RTB101 |
| Parkinson’s disease              | Pingolimod, NBT-NM108, IMU-838 |
| Multiple sclerosis               | GLS-1200 |
| Sinusitis chronic                | Pyridostigmine Bromide, Zilucoplan |
| Myasthenia gravis                | Chlorpromazine, Valproate/Quetiapine |
| **Antipsychotic**                | Brexanolone, Fluoxetine, Fluvoxamine |
| **Antidepressant**               | Ketamine, Dexmedetomidine, Isoflurane, Propofol, Sevoflurane, Thalidomide |
| **Insomnia**                     | Melatonin, Ramelteon |
| **Neural product**               | Anise, ArtemiC, Brazilian Green Propolis Extract [EPP-AF], Cannabis/ Cannabidiol, Crocetin, Deglycyrrhizinated Licorice, Diosmin, Escin, Essential oils, Glycine, Guduchi Ghan, Hesperidin, Honey, Indian Costus, Iota-Carageenan, Isoquercetin, Microcrystalline Cellulose, Nigella sativa, Nuvastatic, Plant Polyphenol, P2Et-Caesalpinia spinosa extract, Quercetin, Vernonia amygdalina, Yinhu Qingwen Granula |
| **Neuroprotective**              | Crocetin, Tranenuron or NA-831, AT-001 |
| Nicotine replacement therapy     | Nicotine patch |
| **Pulmonary disorders**          | Alpha-1-antitrypsin, Alvelestat, Anluohuaxian, Auxora, Bromhexine, Dornase Alfa, Ensifentrine, Lucinactant, Montelukast, Nintedanib, N-acetylcysteine, Pemziviptadil, Prolastin, Poractant alfa, Pulmozyme, Razuprotafib, BLD-2660, C21, LAU-7b, MK 5475, MRx-4DP0004, PLN-74809, PUL-042, TD139, SN0001 |
| **Radioprotective**              | BIO 300 |
| **Sarcopenia**                   | BIO101 |
| **Sexual dysfunction**           | Aviptadil, Sildenafil |
| **Vasomodulator**                | Almitrine, Iloprost, Pentoxifylline, Regadenoson, Sulodexide |

Some drugs may have more than one effect (e.g. anti-inflammatory and anti-cancer) or are used for more than one listed disease.

Lopinavir, a HIV type 1 aspartate protease inhibitor, showed SARS-CoV-2 inhibitory activity in vitro.\textsuperscript{17,22} Ritonavir is combined with lopinavir to increase its plasma half-life through the inhibition of cytochrome P450.\textsuperscript{17} Lopinavir/ritonavir is being investigated in 74 clinical trials. In their
study with hospitalized adult patients with severe COVID-19, Cao et al. concluded that no benefit was observed with lopinavir/ritonavir treatment. In another open-label randomized phase II trial by Hung et al., a triple combination of IFN-β-1b and lopinavir/ritonavir was proven to be safe and superior to lopinavir/ritonavir, with patients showing alleviation of symptoms, shortened duration of viral shedding, and shortened hospital stay.

In monotherapy, umifenovir, which inhibits membrane fusion of the influenza virus, was shown to be superior to lopinavir/ritonavir in treating COVID-19. No viral load was detected in the umifenovir group after 14 days of admission, but the viral load was found in 44.1% of patients treated with lopinavir/ritonavir. Also, favipiravir significantly improved the latency to relief for pyrexia and cough. The combination of umifenovir + lopinavir/ritonavir indicates a faster reduction in viral load, preventing over-stimulation of the immune system, hence diminishing the severity, duration, and infectiveness of the illness when compared with lopinavir/ritonavir treatment.

Ribavirin, which is usually used for hepatitis C treatment and is activated by adenosine kinase to ribavirin triphosphate (RTP), binds to the nucleotide-binding site and prevents further nucleotide addition and acts disrupting 5' CAP addition to viral mRNA. Ribavirin is being investigated in 18 clinical trials to treat COVID-19. Tong et al. conducted a trial with severe COVID-19 patients, showing no association with negative conversion time for real-time polymerase chain reaction (PCR) for SARS-CoV-2 test and the ribavirin therapy is not associated with improved mortality rate.

Other anti-hepatitis C virus drugs, such as daclatasvir and sofosbuvir, showed in vitro antiviral activity against SARS-CoV-2. Both antivirals prevented virus-induced neuronal apoptosis and the release of cytokine storm-related inflammatory mediators, respectively. Daclatasvir also targeted secondary RNA structures in the SARS-CoV-2 genome. Sofosbuvir is being investigated in 12 clinical trials, and daclatasvir is being investigated in 10 clinical trials for the treatment of COVID-19. Eslami et al. conducted a trial where severe COVID-19 patients treated with sofosbuvir/daclatasvir had lower mortality than only ribavirin-treated patients. Other studies have suggested that sofosbuvir/daclatasvir improves survival and clinical recovery in patients with moderate-to-severe COVID-19.

Some experimental drugs developed for other viral diseases that have not yet been approved by regulatory agencies are also being evaluated for the treatment of COVID-19, such as ASC09 F (HIV), AT-527 (hepatitis C), DAS181 (parainfluenza), XC221 (influenza), and galidesivir. In preclinical studies, galidesivir (BCX4430) has been shown to act as a non-obligate RNA chain terminator, which can inhibit viral RNA polymerases of a wide array of RNA viruses, including flaviviruses (yellow fever and Zika virus), filoviruses (Ebola virus and Marburg virus), and coronaviruses (SARS-CoV and MERS-CoV). Target-based virtual screening and molecular docking results have shown that the antiviral galidesivir has promise against SARS-CoV-2 since it tightly binds to the RNA-dependent RNA polymerase. Currently, human trials are completed in Brazilian hospitals to evaluate the pharmacokinetics, safety, and antiviral activity of galidesivir in subjects with yellow fever and COVID-19 (NCT03891420).

Antiparasitic and antibacterial drugs applied to treat COVID-19. Some drugs normally used as antiparasitic drugs have been evaluated in the treatment of COVID-19, such as artemisinin, atovaquone, chloroquine/hydroxychloroquine, ivermectin, levamisole, mefloquine, niclosamide, nitazoxanide, primaquine, pyronaridine-artesunate, quinine, and fafenoquine (Table 2). Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic agent, with demonstrated antiviral effects against HIV, Zika virus, and dengue virus. Vero/hSLAM cells infected with SARS-CoV-2 were exposed to 5 µM ivermectin, with 93% reduction in viral RNA present in the supernatant (indicative of released virions) of samples treated with ivermectin after 24 h, and a 5000-fold reduction in viral RNA compared with the control was found after 48 h. The authors proposed that the drug may have antiviral effects by inhibiting the importin (IMP) α/β receptor, which is responsible for transmitting viral proteins into the host cell nucleus. We found 88 clinical trials evaluating this drug until August 2022. Although randomized controlled
trials are needed to confirm the effects of ivermectin for the treatment of COVID-19, a study involving 280 patients showed lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement.\textsuperscript{38} Another study compared the viral clearance in 400 COVID-19 patients treated with ivermectin/doxycycline or hydroxychloroquine/azithromycin. The clearance was 132 (66\%) on day 5 and 167 (83.5\%) on day 6 in the group treated with ivermectin, whereas there was 154 (77\%) viral clearance on the 11th day and 163 (81.5\%) viral clearance on 12th day of hydroxychloroquine ingestion. The authors concluded that ivermectin and doxycycline is a safe combination that was found to be effective in terms of early viral clearance in patients with mild-to-moderate COVID-19.\textsuperscript{41} A clinical trial of ivermectin plus doxycycline for the treatment of COVID-19 showed lower risk of mortality in patients treated with these drugs (NCT04523831). It is important to remember that FDA has not approved ivermectin for use in treating or preventing COVID-19. According to The COVID-19 Treatment Guidelines by National Institutes of Health (NIH), there are insufficient data for recommendation either for or against the use of ivermectin for the treatment of COVID-19 and more studies are needed.

Chloroquine and hydroxychloroquine, which are used in the treatment of malaria and autoimmune disorders, have been the focus of great public attention.\textsuperscript{42,43} Some preliminary studies have shown that hydroxychloroquine is effective at inhibiting SARS-CoV-2 infection \textit{in vitro}, with less toxicity, and it is more potent than chloroquine.\textsuperscript{44,45} However, large-scale randomized controlled trials have failed to show any survival benefit of such drug therapy in this disease.\textsuperscript{46–48} Despite all this information, these drugs are being evaluated in 249 clinical trials, even in comparison or in combination with other drugs. Seventy-one of these studies analyze the combination of hydroxychloroquine and azithromycin. On 28 March 2020, the US FDA has issued the United States of America (USA) for the inclusion of chloroquine and hydroxychloroquine in the treatment of COVID-19. Subsequently, on 15 June 2020, the US FDA revoked the emergency use authorization based on its ongoing analysis. The FDA further stated that both of these drugs show no benefit on mortality or in speeding recovery and hence are unlikely to be effective in treating COVID-19 patients. On 27 May 2021, NIH published The COVID-19 Treatment Guidelines based on an assessment of the collective evidence from several clinical studies that recommends against the use of these drugs for COVID-19 prophylaxis or treatment because there were no differences between treated groups and placebo. In addition, there were reports of adverse events after using these drugs (https://www.covid19treatmentguidelines.nih.gov/). A review study on these drugs emphasizes the need for evidence-based treatment approaches from large randomized clinical trials to confront the ongoing COVID-19 pandemic and not the mere observational study that mislead the public healthcare system, which paralyzes the entire world.\textsuperscript{49}

Another broad-spectrum antiparasitic, nitazoxanide, has shown antiviral activity against MERS-CoV with inhibition of the production of pro-inflammatory cytokines tumor necrosis factor \(\alpha\) (TNF-\(\alpha\)), IL-2, IL-6, and IL-8.\textsuperscript{50} A recent review evaluated nine nitazoxanide clinical trials, concluding that this drug demonstrates a good safety profile at the approved doses; however, further evidence is required regarding hepatorenal and cardiovascular effects as well as teratogenicity. There were 31 nitazoxanide clinical trials underway worldwide up to August 2022. A recent study showed that 78\% and 57\% of patients in the nitazoxanide and placebo groups, respectively, reported complete resolution of symptoms at the 1-week follow-up. The viral load was also reduced after treatment with nitazoxanide compared with placebo, and no serious adverse events were observed.\textsuperscript{51}

\textbf{Anti-cancer drugs repositioned to COVID-19 treatment.} Originally developed for cancer treatment, opaganib, a sphingosine kinase-2 (SK2) selective inhibitor, is thought to be an anti-inflammatory and potential antiviral drug for COVID-19. Opaganib demonstrated potent anti-SARS-CoV-2 activity, achieving complete blockage of viral replication in an \textit{in vitro} model of human lung tissue. In a small cohort of severe COVID-19 patients, opaganib was safe and well tolerated, with demonstrated improvement in both clinical and laboratory parameters in all treated patients.\textsuperscript{52} We found four clinical trials evaluating this drug in the treatment of COVID-19, three complete and one withdrawn.
According to investigators, DeltaRex-G, another anti-cancer drug, is the first and, so far, only disease-targeted gene therapy that has the potential to effectively treat COVID-19-induced cytokine storm and respiratory distress syndrome. The hypothesis is that DeltaRex-G can hasten recovery from pneumonia and prevent chronic lung disease by killing the activated immune cells that cause acute respiratory distress syndrome and the proliferative fibroblasts that cause chronic lung disease. DeltaRex-G has been investigated in a phase I/II clinical trial (NCT04378244).

COVID-19 treatment based on immunomodulatory drugs. These drugs are based on immunotherapy approaches aimed at either boosting innate antiviral immune responses or alleviating damage induced by dysregulated inflammatory responses. Corticosteroids, anti-inflammatory drugs, anti-neoplastic agents, monoclonal antibodies, and even food supplements and products of natural origin are being evaluated for the treatment of COVID-19 (Table 2).

The use of systemic glucocorticoids has been discussed in SARS-CoV-2 infection since they may prolong viral clearance. However, it is also known that the underlying pathogenesis of COVID-19 pneumonia is composed of both the direct damage caused by the virus and the excessive immune response from the host. Thus, the administration of drugs such as methylprednisolone would help suppress the unwanted immune reactions. A study indicated that single-dose pulse methylprednisolone (40–500 mg) had no apparent negative impact on SARS-CoV-2 removal or the production of specific IgG, while effectively stopping the inflammatory cascade. Another study also concluded that methylprednisolone could lower the mortality rate in more severe forms of the condition, and it is being evaluated in 74 clinical trials, some of them in phase III.

A prospective meta-analysis of clinical trials of critically patients with COVID-19 showed lower 28-day all-cause mortality after administration of systemic corticosteroids when compared with usual care or placebo. Another anti-inflammatory corticosteroid drug, dexamethasone, has been recently suggested to treat severe COVID-19 patients. Patients on mechanical ventilation or oxygen support who received dexamethasone exhibited lower mortality rates compared with those receiving standard care alone. Currently, 110 clinical trials are underway to assess the risk versus benefit for the use of glucocorticoids in the treatment of COVID-19.

Several natural products and food supplements are also being evaluated for the treatment of patients with COVID-19 because many of these drugs have immunomodulatory effects (Table 2). Colchicine is an alkaloid derived from autumn crocus, which has been used to treat several inflammatory diseases, such as gout, for many years, and it is being investigated in 35 clinical trials for the treatment of COVID-19. The results of a clinical study conducted by Brazilian researchers showed that colchicine can help combat lung inflammation with faster recovery for patients with moderate-to-severe COVID-19.

A nanoparticle formulation for spray administration, called ArtemiC (comprising artemisinin, curcumin, Boswellia, and vitamin C), has been proposed as a treatment for COVID-19. ArtemiC has well-established immunomodulatory activities as demonstrated in vitro and in vivo, and published over the years, diminishing the activity of TNF-α and IL-6 levels which can be relevant to the pathophysiology processes involved in the progressive form of COVID-19. In addition, the active agents have prominent antioxidant, anti-inflammatory, as well as anti-aggregating and anti-microbial activities. In this context, natural compounds, such as curcumin, have shown beneficial effects that make them a promising target in the adjuvant treatment of COVID-19 as recently reviewed. A phase II controlled clinical study designed to evaluate the effect of ArtemiC in patients diagnosed with COVID-19 is being done in hospitals in Israel and India (NCT04382040).

Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) to treat COVID-19. Hypertension and cardiovascular disease are risk factors for death in COVID-19. Angiotensin-converting enzyme 2 (ACE2), an important component of the renin–angiotensin system, serves as the binding site of SARS-CoV-2 [spike (S) protein] and facilitates host cell entry in the lungs. In experimental models, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have been shown to increase
ACE2 expression in several organs, potentially promoting viral cell invasion, although these findings are not consistent across studies.69 Alternatively, ACEIs and ARBs may actually improve mechanisms of host defense or hyperinflammation, ultimately reducing organ injury. Finally, ACEIs and ARBs may have direct renal, pulmonary, and cardiac protective benefits in the setting of COVID-19. Therefore, it is unclear whether ACEIs and ARBs may be beneficial or harmful in patients with COVID-19. Given the high prevalence of hypertension and cardiovascular and renal diseases in the world, the high prevalence of ACEIs or ARBs in these conditions, and the clinical equipoise regarding the continuation versus discontinuation of ACEIs/ARBs in the setting of COVID, a randomized trial is urgently needed. The aim of the NCT04338009 trial with 152 participants was to assess the clinical impact ACE inhibitors and angiotensin receptor blockers on outcomes in patients hospitalized with COVID-19. According to this study, compared with discontinuation of renin–angiotensin system inhibitors, continuation had no effect on the global rank score.66 Another study with 611 patients with COVID-19 showed that ACEI exposure significantly reduced the risk of severe disease [odds ratio (OR) = 0.37, 95% confidence interval (CI): 0.15–0.87, p = 0.03]. ACEI exposure was associated with milder infiltrations seen on baseline computed tomography, lower C-reactive protein and ferritin, higher monocytes, shorter hospitalization, and less requirement for specific empirical treatments (favipiravir and meropenem). The data suggest that exposure to ACEI drugs may have favorable effects in the context of COVID-19 pneumonia.67 According to The COVID-19 Treatment Guidelines by NIH, patients with COVID-19 who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) for cardiovascular disease (or other non-COVID-19 indications) should not discontinue these medications unless discontinuation is otherwise warranted by their clinical condition. The COVID-19 Treatment Guidelines recommends against the use of ACE inhibitors or ARBs for the treatment of COVID-19, except in a clinical trial. Additional investigations of the role of ACE inhibitors, ARBs, and recombinant human ACE2 in the management of COVID-19 are underway. Human recombinant soluble ACE2 (hrsACE2; APN01) can significantly block early SARS-CoV-2 infections by a factor of 1.000–5.000.68 HrsACE2 has entered a placebo-controlled, double-blind, phase IIb trial in severe COVID-19 patients (NCT04335136), acting as a molecular decoy to block virus entry, and as a regulator of the renin–angiotensin system. Remdesivir has received authorization for COVID-19 and has been shown to improve outcomes; however, the dose of remdesivir is limited by hepatic and kidney toxicity. Monteil et al.69 evaluated the therapy using remdesivir with recombinant soluble ACE2 targeting two different modalities of SARS-CoV-2 life cycle: cell entry via its receptor ACE2 and intracellular viral RNA replication. This combination treatment markedly improved their therapeutic windows against SARS-CoV-2 in vitro models. The data demonstrated that combining two therapeutic modalities with different targets exhibit strong additive effects at subtoxic concentrations. Some clinical trials are evaluating the combination of recombinant bacterial ACE2 receptors and drugs (NCT04382950; NCT04375046).

Monoclonal antibodies as therapy against SARS-CoV-2 and to treat COVID-19

According to the Chinese Antibody Society, most of the antibodies that are candidates for use as therapy against SARS-CoV-2 have ‘Discovery’ status (33.3%) followed by ‘Preclinical’ status (25.8%).

Most of the studies uses monoclonal antibodies (78.3%), followed by single domain Ab (6.6%) and fusion protein (6.1%). The United States has the largest number of studies on the subject, followed by China and the United Kingdom.

Monoclonal antibodies are also classified as ‘Drug Interventions’ according to ClinicalTrials.gov, and some of these antibodies have been developed especially for the treatment of COVID-19, such as LY3819253 (LY-CoV555 or bamlanivimab), LY3832479 (LY-CoV016), and BAT2020. A phase I/II study to assess the safety, pharmacokinetics, immunogenicity, and efficacy of BAT2020 is being carried out in patients hospitalized with COVID-19 (NCT04432766). LY-CoV555 is a potent, neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2, and it was identified from a blood sample taken from one of the first US patients who recovered from COVID-19. The LY-CoV555 clinical trial has successfully completed enrollment and primary safety assessments in a phase I study of
hospitalized patients with COVID-19 (NCT04411628), and long-term follow-up is ongoing as a phase II/III study in people recently diagnosed with COVID-19 in the ambulatory setting (NCT04427501). Recently, the phase III study of LY-CoV555 for the prevention of COVID-19 in residents and staff at long-term care facilities has begun (NCT04497987). This drug received emergency use authorization from the FDA on 10 November 2020.8 In addition, LY-CoV555 is being tested in combination with LY-CoV016, which binds a different epitope in the SARS-CoV-2 spike region. The trial is currently enrolling a larger confirmatory cohort of higher risk patients and is testing the ability of the antibody combination to reduce the number of patients with persistently high viral load and to reduce COVID-related hospitalizations.

The monoclonal antibody that most presents clinical trials use is tocilizumab, which is a recombinant humanized anti-human IL-6 receptor. IL-6 takes center stage in COVID-19 because it acts as a cytokine storm amplifier, inducing the production of more pro-inflammatory cytokines and the production of acute phase proteins by the liver, weakening the papillary muscle and leading to myocardial dysfunction.6,7 Seventy randomized trials with tocilizumab are ongoing, and some of these are in phases III and IV. Tocilizumab might be useful in the treatment of COVID-19 patients with a hyperinflammatory state, presenting lower hazards of intubation or death, but the efficacy is under discussion.14–16,70

Baricitinib, an oral JAK1/JAK2 inhibitor, has been proven to be promising for lowering airway inflammation in SARS-CoV-2-infected rhesus macaques, leading to fast and potent suppression of the alveolar macrophage-derived production of cytokines and chemokines responsible for inflammation and neutrophil recruitment.16 Eighteen clinical trials are ongoing, including in combination with remdesivir (NCT04401579).

Several other monoclonal antibodies are being evaluated for COVID-19 (Table 2). Most of them target S protein, GM-CSF or GM-CSFR, IL-6, or IL-6R. Among them, sarilumab, an anti-IL6R, is present in 12 clinical trials at different stages; canakinumab, an inhibitor of IL-1beta, is present in 6 clinical trials; and clazakizumab (targets IL-6) and mavrilimumab (targets GM-CSFRα).

**Convalescent plasma from patients who have recovered from COVID-19**

Convalescent plasma (CP) therapy is another procedure being tested for COVID-19. Patients who have recovered from COVID-19 should have an elevated number of polyclonal antibodies produced by the immune system to prevent new circles of infection by SARS-CoV-2.71,72 Clinical trials have provided robust evidence that the transfusion of CP is safe in hospitalized patients with COVID-19, supporting the notion that earlier administration of plasma within the clinical course of COVID-19 is more likely to reduce mortality.73–75 One limitation of this therapy is the variability in potency found in the sera of recovered patients in neutralizing the antigen.76 A study in the United States (NCT04343261) demonstrated that the early administration of CP in the group of patients with severe illness resulted in improved outcomes.77

The United States has the largest number of studies addressing this theme, totaling 184 clinical trials, and the second region with the largest number of studies is Europe (especially Italy and Spain). South America has a significant number of studies when compared with certain regions, such as North and East Asia (Figure 2).

There are 84 studies with completed status. Most of the studies are in recruitment status (a total of 73) or not yet recruiting status (a total of 18), and 17 of the studies were classified as observational.

**Mesenchymal cell therapy to treat COVID-19**

We found 70 clinical trials evaluating mesenchymal stem cells (MSCs) for the treatment of patients with COVID-19 (Figure 2). MSCs are non-specialized multipotent cells that have self-renewal and the capacity to differentiate into diverse cell types. MSCs can be isolated from peripheral blood, bone marrow, the umbilical cord, or the placenta, and after expansion, they can be administered to patients with cytokine storm and sepsis because of their powerful anti-inflammatory and immunomodulatory abilities.78 Some clinical studies have suggested that transplantation of MSCs can improve the outcome of COVID-19 patients, possibly by regulating the inflammatory response and promoting the recovery of antiviral immune cells and organs.78–80
Conclusion
The whole world has come together in the search for effective therapies for the treatment or prevention of COVID-19. Difficulties in terms of higher dose production, storage, and transportation may be challenges for pharmaceutical industries during vaccine distribution. On the contrary, efforts have been made to create different vaccines with different approaches so that they can be used by the entire population. Moreover, the search for new drugs or the repositioning of available drugs can be useful for treating COVID-19 until the virus is eradicated. Although there has been a great effort by researchers around the world, the higher number of clinical trials in Europe and the United States suggests the need for public and private investments in the development of cutting-edge research globally. Nevertheless, the different types of studies and clinical trials around the world have the same goal of discovering effective methods of treatment and prevention of COVID-19. Here, we summarized about 4,148 clinical trials that evaluated new drugs or drug repositioning in the treatment of COVID-19. Each study brings the pros or cons related to the use of drugs with important results of antiviral new drugs that are in phase II of the study. Monoclonal antibodies have been presenting good results targeting SARS-CoV-2 neutralizing the virus, as remdesivir, and the monoclonal antibodies targeting pro-inflammatory cytokines or signaling pathways to avoid the cytokine storm what can help patients suffering from the clinical manifestations of COVID-19.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Author contributions
Josidel Conceição Oliver: Conceptualization; Data curation; Methodology; Writing – original draft.
Evandro Neves Silva: Data curation; Formal analysis; Methodology; Writing – original draft.
Leticia Martins Soares: Conceptualization; Data curation; Methodology; Writing – original draft.
Gislaine Cristina Scodeler: Data curation; Methodology; Writing – original draft.
Ana de Souza Santos: Data curation; Methodology.
Patrícia Paiva Corsetti: Conceptualization; Data curation; Formal analysis; Methodology; Project administration; Resources; Supervision.
Carlos Roberto Prudêncio: Conceptualization; Data curation; Formal analysis; Funding acquisition; Project administration; Resources; Supervision; Validation; Writing – original draft.
Leonardo Augusto de Almeida: Conceptualization; Data curation; Formal analysis; Project administration; Resources; Supervision; Validation; Writing – original draft.

Acknowledgements
We thank the Brazilian Ministry of Education (MEC) for the financial support and the institutions to which the present authors are affiliated.

Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) (Finance Code 001), Federal University of Alfenas (EDITAL No 002/2020 – PRPPI/REITORIA), and the Brazilian Ministry of Education (MEC). The funders had no role in study design, data collection, and analysis; decision to publish; or preparation of the manuscript. There was no additional external funding received for this study.

Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Availability of data and materials
The datasets generated and/or analyzed during the current study are available in the ClinicalTrials.gov repository.

ORCID iD
Leonardo Augusto de Almeida https://orcid.org/0000-0003-1886-5080
References

1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020; 579: 270–273.

2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395: 497–506.

3. WHO. WHO Director-General’s remarks at the media briefing on 2019-nCoV on 11 February 2020, https://www.who.int/director-general/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020

4. Santacroce L, Charitos IA, Carretta DM, et al. The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection. *J Mol Med* 2021; 99: 93–106.

5. Petersen E, Koopmans M, Go U, et al. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. *Lancet Infect Dis* 2020; 20: e238–e244.

6. WHO. WHO coronavirus disease (COVID-19) dashboard, 2020, https://covid19.who.int/

7. Bakker B, Jones RM, Anson BJ, et al. Discovery of a novel inhibitor of coronavirus 3CL protease as a clinical candidate for the potential treatment of COVID-19. *bioRxiv Prepr Serv Biol*. Epub ahead of print 12 February 2021. DOI: 10.1101/2020.09.12.293498.

8. de Vries M, Mohamed AS, Prescott RA, et al. Comparative study of a 3CL pro inhibitor and remdesivir against both major SARS-CoV-2 clades in human airway models. *bioRxiv Prepr Serv Biol* 2020.

9. Singh TU, Parida S, Lingaraju MC, et al. Drug repurposing approach to fight COVID-19. *Pharmacol Rep* 2020; 72: 1479–1508.

10. Fischer WA, Eron JJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. *Sci Transl Med* 2022; 14: eabf7430.

11. Abdelnabi R, Foo CS, Jonghe SD, et al. Molnupiravir inhibits replication of the emerging SARS-CoV-2 variants of concern in a hamster infection model. *J Infect Dis* 2021; 224: 749–753.

12. Bernal AJ, Gomes-da-Silva MM, Musungaike DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. *N Engl J Med* 2022; 386: 509–520.

13. Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. *ACS Cent Sci* 2020; 6: 672–683.

14. Warren T, Jordan R, Lo M, et al. Nucleotide prodrug GS-5734 is a broad-spectrum filovirus inhibitor that provides complete therapeutic protection against the development of ebola virus disease (EVD) in infected non-human primates. *Open Forum Infect Dis* 2015; 2: LB-2.

15. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. *Sci Transl Med* 2017; 9: eaal3653.

16. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020; 30: 269–271.

17. Choy KT, Wong AY, Kaeppreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. *Antiviral Res* 2020; 178: 104786.

18. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe covid-19. *N Engl J Med* 2020; 382: 2327–2336.

19. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 – final report. *N Engl J Med* 2020; 383: 1813–1826.

20. Yamamura H, Matsuura H, Nakagawa J, et al. Effect of favipiravir and an anti-inflammatory strategy for COVID-19. *Crit Care* 2020; 24: 413.

21. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. *Engineering (Beijing)* 2020; 6: 1192–1198.

22. Choo CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax* 2004; 59: 252–256.

23. Cao B, Wang Y, Wen D, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe covid-19. *N Engl J Med* 2020; 382: 1787–1799.

24. Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet (London, England)* 2020; 395: 1695–1704.
25. Zhu Z, Lu Z, Xu T, et al. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. *J Infect* 2020; 81: e21–e23.

26. Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. *MedRxiv* 2020.

27. Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against coronavirus disease 2019: a retrospective cohort study. *J Infect* 2020; 81: e1–e5.

28. Te HS, Randall G and Jensen DM. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. *Gastroenterol Hepatol (NY)* 2007; 3: 218–225.

29. Khalaf K, Papp N, Chou JT, et al. SARS-CoV-2: pathogenesis, and advancements in diagnostics and treatment. *Front Immunol* 2020; 11: 570927.

30. Tong S, Su Y, Yu Y, et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. *Int J Antimicrob Agents* 2020; 56: 106114.

31. Sacramento CQ, Fintelman-Rodrigues N, Temerozo JR, et al. The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2. *Biorxiv Prepr Serv Biol* 2020.

32. Sadeghi A, Ali Asgari A, Norouzi A, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. *J Antimicrob Chemother* 2020; 75: 3379–3385.

33. Abbaspour Kasgari H, Moradi S, Shabani AM, et al. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial. *J Antimicrob Chemother* 2020; 75: 3373–3378.

34. Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. *Nature* 2014; 508: 402–405.

35. Julander JG, Siddharthan V, Evans J, et al. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. *Antiviral Res* 2017; 137: 14–22.

36. Aftab SO, Ghouri MZ, Masood MU, et al. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach. *J Transl Med* 2020; 18: 275.

37. Elfiky AA. Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. *Life Sci* 2020; 253: 117592.

38. Wagstaff KM, Sivakumaran H, Heaton SM, et al. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. *Biochem J* 2012; 443: 851–856.

39. Ketkar H, Yang L, Wormser GP, et al. Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system. *Diagn Microbiol Infect Dis* 2019; 95: 38–40.

40. Caly L, Druce JD, Catton MG, et al. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res* 2020; 178: 104787.

41. Rahman MA, Iqbal SA, Islam MA, et al. Comparison of viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients. *J Bangladesh Coll Physicians Surg* 2020; 38: 5–9.

42. Khuroo MS. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. *Int J Antimicrob Agents* 2020; 56: 106101.

43. Katz SJ and Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. *Curr Opin Rheumatol* 2011; 23: 278–281.

44. Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* 2020; 71: 732–739.

45. Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov* 2020; 6: 16.

46. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ* 2020; 2020: m1849.

47. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate
as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. JAMA Netw Open 2020; 3: e208857.

48. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv 2020.

49. Manivannan E, Karthikeyan C, Hari Narayana Moorthy NS, et al. The rise and fall of chloroquine/hydroxychloroquine as compassionate therapy of COVID-19. Front Pharmacol 2021; 12: 584940.

50. Rossignol JF. Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus. J Infect Public Health 2016; 9: 227–230.

51. Rocco PRM, Silva PL, Cruz FF, et al. Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial. medRxiv 2020.

52. Kurd R, Ben-Chetrit E, Karameh H, et al. Compassionate use of opaganib for patients with severe COVID-19. medRxiv 2020.

53. Tu Y-F, Chien C-S, Yarmishyn AA, et al. A review of SARS-CoV-2 and the ongoing clinical trials. Int J Mol Sci 2020; 21: 2657.

54. Liu J, Zheng X, Huang Y, et al. Successful use of methylprednisolone for treating severe COVID-19. J Allergy Clin Immunol 2020; 146: 325–327.

55. Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med (Lausanne) 2020; 7: 170.

56. Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. JAMA 2020; 324: 1330.

57. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with covid-19 – preliminary report. N Engl J Med 2020; 2020: NEJMoa2021436.

58. Lopes MIF, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: an interim analysis of a randomized, double-blinded, placebo controlled clinical trial. medRxiv 2020.

59. Jovic TH, Ali SR, Ibrahim N, et al. Could vitamins help in the fight against COVID-19? Nutrients 2020; 12: 2550.

60. Cao R, Hu H, Li Y, et al. Anti-SARS-CoV-2 potential of artemisinins in vitro. ACS Infect Dis 2020; 6: 2524–2531.

61. Babaei F, Nassiri-Asl M and Hosseinzadeh H. Curcumin (a constituent of turmeric): new treatment option against COVID-19. Food Sci Nutr 2020; 8: 5215–5227.

62. McCullough PA, Kelly RJ, Ruocco G, et al. Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection. Am J Med 2021; 134: 16–22.

63. Rattis B, Ramos S and Celes MRN. Curcumin as a potential treatment for COVID-19. Front Pharmacol 2021; 12: 675287.

64. Li W, Moore M, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426(6965): 450–454.

65. Mascolo A, Scavone C, Rafaniello C, et al. The role of renin-angiotensin-aldosterone system in the heart and lung: focus on COVID-19. Front Pharmacol 2020; 12: 667254.

66. Cohen JB, Hanff TC, William P, et al. Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respir Med 2021; 9: 275–284.

67. Şenkal N, Meral R, Medetalibeyoğlu A, et al. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19. Anatol J Cardiol 2020; 24: 21–29.

68. Monteli V, Kwon H, Prado P, et al. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell 2020; 181: 905–913.

69. Monteil V, Dyczynski M, Lauschke V, et al. Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection. EMBO Mol Med 2021; 13: e13426.

70. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 2018; 9: e00221-18.

71. Saha RP, Sharma AR, Singh MK, et al. Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19. Front Pharmacol 2020; 11: 1258.
72. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. *J Med Virol* 2020; 92: 1890–1901.

73. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. *JAMA* 2020; 323: 1582–1589.

74. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci USA* 2020; 117: 9490–9496.

75. Joyner MJ, Bruno KA, Klassen SA, et al. Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients. *Mayo Clin Proc* 2020; 95: 1888–1897.

76. Marano G, Vaglio S, Pupella S, et al. Convalescent plasma: new evidence for an old therapeutic tool? *Blood Transfus* 2016; 14: 152–157.

77. Ibrahim D, Dulipsingh L, Zapatka L, et al. Factors associated with good patient outcomes following convalescent plasma in COVID-19: a prospective phase II clinical trial. *Infect Dis Ther* 2020; 9: 913–926.

78. Leng Z, Zhu R, Hou W, et al. Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. *Aging Dis* 2020; 11: 216–228.

79. Liang B, Chen J, Li T, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. *Medicine (Baltimore)* 2020; 99: e21429.

80. Zhang Y, Ding J, Ren S, et al. Intravenous infusion of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. *Stem Cell Res Ther* 2020; 11: 207.